The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000856314p
Ethics application status
Help: Ethics application status
Not yet submitted
Date submitted
Help: Date submitted
6/06/2026
Date registered
Help: Date registered
14/07/2026
Date last updated
Help: Date last updated
14/07/2026
Date data sharing statement initially provided
Help: Data sharing statement date
14/07/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
A pilot randomised controlled trial evaluating the feasibility of a patient-held difficult intravenous access (DIVA) card for adults with difficult intravenous access at Sir Charles Gairdner Hospital, Western Australia.
Scientific title
Feasibility of a patient-held difficult intravenous access card: a pilot randomised controlled trial with embedded qualitative interviews.
Additional trial identifiers [1] 317508 0
nil
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Difficult peripheral intravenous access 342240 0
Condition category
Condition code
Anaesthesiology 338360 338360 0 0
Other anaesthesiology
Public Health 338467 338467 0 0
Health service research

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Intervention: Participants allocated to the intervention group will receive a patient-held difficult intravenous access card, approximately the same size as a credit card. The card is intended to alert healthcare staff that the participant has a history of difficult peripheral intravenous access and may require early escalation to an experienced cannulator and/or vascular access support, such as ultrasound-guided cannulation. The card will be provided to eligible adult patients identified as having difficult intravenous access during their hospital admission. Participants will be advised to present the card to healthcare staff at any Western Australian hospital if they require future peripheral intravenous cannulation during the 12-month study follow-up period.

Who delivers it: The intervention will be delivered by members of the vascular access team, or by delegated research or clinical staff employed in the emergency department who have been trained in the study protocol. These staff will have relevant clinical expertise in peripheral intravenous cannulation, identification of difficult intravenous access, and escalation pathways for patients requiring vascular access support.

How is it delivered: The intervention will be delivered face to face and individually to eligible participants. Participants randomised to the intervention group will be given the patient-held DIVA card during their hospital admission. The card will be explained verbally, including its purpose and how the participant should use it. Participants will be advised to show the card to healthcare staff if they require future peripheral intravenous cannulation during the 12-month study follow-up period.

How often is it delivered: The DIVA card will be provided once following randomisation. The brief explanation of the card is expected to take approximately 5 minutes. Participants will keep the card and may use it for any subsequent peripheral intravenous cannulation episodes during the 12-month study follow-up period.

Where is it delivered: The intervention will be delivered in the hospital setting, such as the participant’s ward, emergency department, or other clinical area where the participant is identified as eligible and enrolled in the study. The participating site is Sir Charles Gairdner Hospital.

Adherence: Participants allocated to the intervention group will receive brief verbal and written instructions advising them to keep the DIVA card with them and present it to healthcare staff during future peripheral intravenous cannulation episodes over the 12-month study follow-up period. Intervention adherence will be monitored using participant-reported follow-up surveys delivered via SMS, which will ask whether the participant retained the card, had it available, and presented it during subsequent cannulation episodes. Reported non-use, loss of the card, or failure to present the card will be recorded as feasibility outcomes. Adherence to study follow-up procedures will also be assessed through SMS survey response rates, survey completion rates, and data completeness.

The overall study duration will be 24 months, comprising a 12-month intervention/recruitment period and a 12-month participant follow-up period. Participants allocated to the intervention group will be advised to use and present the DIVA card for any future peripheral intravenous cannulation episodes occurring during their 12-month follow-up period.
Intervention code [1] 334299 0
Behaviour
Intervention code [2] 334300 0
Treatment: Other
Description of the comparator or control
Participants allocated to the control group will receive standard peripheral intravenous catheter care without provision of a patient-held Difficult Intravenous Access (DIVA) card. Standard care may include usual clinical assessment, peripheral intravenous cannulation attempts, escalation to more experienced clinicians or vascular access clinicians, and use of ultrasound-guided cannulation where clinically indicated according to local practice.
Control group participants will receive the participant information sheet, complete electronic enrolment and consent procedures, and receive the same SMS follow-up surveys as the intervention group. They will not receive the DIVA card or DIVA card instructions. Outcomes will be collected using the same follow-up procedures as the intervention group.

Control group
Active

Outcomes
Primary outcome [1] 345677 0
Primary outcome 1: Recruitment feasibility
Timepoint [1] 345677 0
Recruitment feasibility will be assessed continuously throughout the recruitment period. Participants will be recruited for up to 12 months, or until the target sample size is reached, whichever occurs first. Final assessment of recruitment feasibility will occur at the end of the recruitment period, either when the target sample size is reached or 12 months after recruitment/intervention commencement.
Primary outcome [2] 345898 0
Primary outcome 2: Retention feasibility
Timepoint [2] 345898 0
Retention feasibility will be assessed from the time each participant is enrolled and randomised, and throughout their follow-up period. Participants will be followed for up to 12 months from enrolment/randomisation. Final assessment of retention feasibility will occur once all enrolled participants have completed their required follow-up, up to 12 months after the final participant is enrolled/randomised, and up to 24 months after recruitment/intervention commencement.
Primary outcome [3] 345899 0
Primary outcome 3: Intervention adherence
Timepoint [3] 345899 0
Intervention adherence will be assessed from the time each participant is enrolled and randomised to the intervention group, and throughout their follow-up period. Participants allocated to the intervention group will be followed for up to 12 months from enrolment/randomisation. Final assessment of intervention adherence will occur once all intervention group participants have completed their required follow-up, up to 12 months after the final intervention group participant is enrolled/randomised, and up to 24 months after recruitment/intervention commencement.
Secondary outcome [1] 462837 0
Secondary outcome 1: First-pass success
Timepoint [1] 462837 0
First-pass success will be assessed following each reported peripheral intravenous cannulation episode during each participant’s follow-up period. Outcome data will be collected using participant-reported follow-up surveys and/or cannulation-related survey data. Assessment may occur from the time each participant is enrolled and randomised, as participants recruited earlier in the study may report cannulation episodes while recruitment of other participants is ongoing. Final assessment will occur at completion of participant follow-up, up to 12 months after the final participant is enrolled/randomised, and up to 24 months after recruitment/intervention commencement.
Secondary outcome [2] 462838 0
Secondary outcome 2: Total number of cannulation attempts
Timepoint [2] 462838 0
Total number of cannulation attempts will be assessed following each reported peripheral intravenous cannulation episode during each participant’s follow-up period. Outcome data will be collected using participant-reported follow-up surveys and/or cannulation-related survey data. Assessment may occur from the time each participant is enrolled and randomised, as participants recruited earlier in the study may report cannulation episodes while recruitment of other participants is ongoing. Final assessment will occur at completion of participant follow-up, up to 12 months after the final participant is enrolled/randomised, and up to 24 months after recruitment/intervention commencement.
Secondary outcome [3] 462839 0
Secondary outcome 3: Procedural pain
Timepoint [3] 462839 0
Procedural pain will be assessed following each reported peripheral intravenous cannulation episode during each participant’s follow-up period. Outcome data will be collected using participant-reported follow-up surveys and/or cannulation-related survey data. Assessment may occur from the time each participant is enrolled and randomised, as participants recruited earlier in the study may report cannulation episodes while recruitment of other participants is ongoing. Final assessment will occur at completion of participant follow-up, up to 12 months after the final participant is enrolled/randomised, and up to 24 months after recruitment/intervention commencement.
Secondary outcome [4] 462840 0
Secondary outcome 4: Escalation to senior clinician or vascular access team
Timepoint [4] 462840 0
Escalation to a senior clinician or vascular access team will be assessed following each reported peripheral intravenous cannulation episode during each participant’s follow-up period. Outcome data will be collected using participant-reported follow-up surveys and/or cannulation-related survey data. Assessment may occur from the time each participant is enrolled and randomised, as participants recruited earlier in the study may report cannulation episodes while recruitment of other participants is ongoing. Final assessment will occur at completion of participant follow-up, up to 12 months after the final participant is enrolled/randomised, and up to 24 months after recruitment/intervention commencement.
Secondary outcome [5] 462841 0
Secondary outcome 5: Use of ultrasound-guided cannulation
Timepoint [5] 462841 0
Use of ultrasound-guided cannulation will be assessed following each reported peripheral intravenous cannulation episode during each participant’s follow-up period. Outcome data will be collected using participant-reported follow-up surveys and/or cannulation-related survey data. Assessment may occur from the time each participant is enrolled and randomised, as participants recruited earlier in the study may report cannulation episodes while recruitment of other participants is ongoing. Final assessment will occur at completion of participant follow-up, up to 12 months after the final participant is enrolled/randomised, and up to 24 months after recruitment/intervention commencement.
Secondary outcome [6] 464067 0
Primary Outcome 4: Survey Completion
Timepoint [6] 464067 0
Survey completion will be assessed throughout each participant’s follow-up period, from enrolment/randomisation until completion of follow-up. Participants will be followed for up to 12 months from enrolment/randomisation. Final assessment of survey completion will occur once all enrolled participants have completed their required follow-up, up to 12 months after the final participant is enrolled/randomised, and up to 24 months after recruitment/intervention commencement.
Secondary outcome [7] 464068 0
Primar Outcome 5: Data completeness
Timepoint [7] 464068 0
Data completeness will be assessed progressively throughout the recruitment and participant follow-up periods. Participants will be followed for up to 12 months from enrolment/randomisation. Final assessment of data completeness will occur once all enrolled participants have completed their required follow-up and data collection has been finalised, up to 12 months after the final participant is enrolled/randomised, and up to 24 months after recruitment/intervention commencement.

Eligibility
Key inclusion criteria
Adults aged 18 years or older who are receiving care at Sir Charles Gairdner Hospital and are identified as having difficult intravenous access by a vascular access clinician or emergency department clinician. Difficult intravenous access may be identified by patient-reported history of difficult cannulation, previous documentation of difficult intravenous access, poor vein visibility or palpability, two or more failed peripheral intravenous cannulation attempts, requirement for ultrasound-guided cannulation, or referral/escalation to a vascular access clinician or more experienced inserter. Participants must be able to provide informed consent and complete electronic enrolment and follow-up procedures, either independently or with assistance where appropriate
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
1) Patient in critical/emergency situation (such as CODE BLUE), immediate life-threatening situation, palliative care not requiring IV procedures or other similar clinical scenario and requiring vascular access*1b. This scenario is left to the discretion of the VAT or ED staff member, and they can determine whether recruitment is appropriate or not.
*1b Emergency Department: Adults classified by Australasian Triage Scale and determined as Category 1 or 2

2) Patient requiring primary vascular access, that is not peripheral IV (such as PICC line or port).

3) Paediatric patients (<18 years old).

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation concealment is maintained by using sequentially numbered, opaque envelopes that are sealed prior to distribution to the participant. The packs will be distributed sequentially and only given out after obtaining informed consent by research investigators.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Participants will be allocated to either intervention group or the control group via individualised randomisation. Randomisation sequence will be performed using computer-generated randomisation software. 1:1 allocation randomisation is likely to be implemented for simplicity. There is no stratification on sex, age, previous treatment or other factors.
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
The nature of this pilot RCT means this study is not powered and has no formal sample size calculation. The focus is on estimating recruitment, adherence and retention to the protocol to inform a future definitive RCT. The target sample size in this study is based on similar studies identified in the literature, a pragmatic approach (Rickard et al., 2024; Ullman et al., 2017) and based on opinions found in recent literature (Lewis et al., 2025; Montgomery, 2025).

---

Lewis, M., Bromley, K., & Joseph, R. (2025). Small numbers, big decisions: guidance for sample size in pilot trials. Bmj, 390, r1885. https://doi.org/10.1136/bmj.r1885

Montgomery, R. (2025). Sample size justification in feasibility studies: moving beyond published guidance. Pilot Feasibility Stud, 11(1), 88. https://doi.org/10.1186/s40814-025-01675-9

Rickard, C. M., Drugeon, B., Ullman, A., Marsh, N. M., Corley, A., Ball, D., O'Brien, C., Kleidon, T. M., Guenezan, J., Couvreur, R., McCarthy, K. L., Seguin, S., Batiot, G., Byrnes, J., Schults, J., Syeda Farah, Z., & Mimoz, O. (2024). Protect peripheral intravenous catheters: a study protocol for a randomised controlled trial of a novel antimicrobial dressing for peripheral intravenous catheters (ProP trial). BMJ open, 14(7). https://doi.org/https://doi.org/10.1136/bmjopen-2024-084313

Ullman, A. J., Kleidon, T., Gibson, V., McBride, C. A., Mihala, G., Cooke, M., & Rickard, C. M. (2017). Innovative dressing and securement of tunneled central venous access devices in pediatrics: a pilot randomized controlled trial. BMC Cancer, 17(1), 595. https://doi.org/10.1186/s12885-017-3606-9

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
WA
Recruitment hospital [1] 29612 0
Sir Charles Gairdner Hospital - Nedlands
Recruitment postcode(s) [1] 45943 0
6009 - Nedlands

Funding & Sponsors
Funding source category [1] 322075 0
University
Name [1] 322075 0
Edith Cowan University Research Training Program (RTP) Scholarship
Country [1] 322075 0
Australia
Primary sponsor type
University
Name
Edith Cowan University
Address
Country
Australia
Secondary sponsor category [1] 325211 0
None
Name [1] 325211 0
Address [1] 325211 0
Country [1] 325211 0
Other collaborator category [1] 283976 0
Hospital
Name [1] 283976 0
Sir Charles Gairdner Hospital, North Metropolitan Health Service
Address [1] 283976 0
Country [1] 283976 0
Australia

Ethics approval
Ethics application status
Not yet submitted
Ethics committee name [1] 320604 0
WA Health Central HREC
Ethics committee address [1] 320604 0
Ethics committee country [1] 320604 0
Australia
Date submitted for ethics approval [1] 320604 0
10/07/2026
Approval date [1] 320604 0
Ethics approval number [1] 320604 0
Ethics committee name [2] 320607 0
Edith Cowan University Human Research Ethics Committee
Ethics committee address [2] 320607 0
Ethics committee country [2] 320607 0
Australia
Date submitted for ethics approval [2] 320607 0
10/07/2026
Approval date [2] 320607 0
Ethics approval number [2] 320607 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 151030 0
Mr Sitthichai Rees
Address 151030 0
Edith Cowan University, School of Nursing and Midwifery, 270 Joondalup Dr, Joondalup WA, 6027
Country 151030 0
Australia
Phone 151030 0
+61 451832955
Fax 151030 0
Email 151030 0
Contact person for public queries
Name 151031 0
Sitthichai Rees
Address 151031 0
Edith Cowan University, School of Nursing and Midwifery, 270 Joondalup Dr, Joondalup WA 6027
Country 151031 0
Australia
Phone 151031 0
+61 451832955
Fax 151031 0
Email 151031 0
Contact person for scientific queries
Name 151032 0
Sitthichai Rees
Address 151032 0
Edith Cowan University, School of Nursing and Midwifery, 270 Joondalup Dr, Joondalup WA, 6027
Country 151032 0
Australia
Phone 151032 0
+61 451832955
Fax 151032 0
Email 151032 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: No. Individual participant data will not be publicly shared due to the small sample size, single-site setting, and potential risk of re-identification, particularly in relation to qualitative interview data and detailed clinical experiences. De-identified aggregate data may be reported in publications, presentations and the final thesis.




What supporting documents are/will be available?

TypeCitationLinkEmailOther DetailsAttachment
Informed consent form  [email protected]
Statistical analysis plan  [email protected]
Study protocol  [email protected]
Ethical approval  [email protected]
Other  [email protected] Participant information sheet
Other  [email protected] Draft cannulation survey
Data dictionary  [email protected]
Other  [email protected] Semi-structured interview guide
Other  [email protected] The DIVA card (the intervention that we are propos... [More Details]


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.